Antibody-drug conjugate

GeneQuantum announces two key leadership appointments

Retrieved on: 
Thursday, September 16, 2021
Pfizer, ICH, SAPA, NDA, Acceleration, PMDA, Novartis, CEO, FDA, CMC, Drug development, University, Antibody-drug conjugate, Patient, Stanford University, EMA, IND, ILDC Energy, Regulatory affairs, Rutgers University, Notre Dame, Strategic planning, Pharmacy, ADC, NMPA, Genentech, Senior, National Quality Research Center, Pleasure, RAC, Cancer, Medical device, Fine chemical

Their joining marks a concrete step forward in our strategic planning of establishing and expanding a world-class clinical and regulatory affairs team.

Key Points: 
  • Their joining marks a concrete step forward in our strategic planning of establishing and expanding a world-class clinical and regulatory affairs team.
  • Their extensive expertise and excellent leadership capability are crucial for the success of the company.
  • They commented, " GeneQuantum has the world's leading Antibody-Drug-Conjugate (ADC) iLDC platform, as well as a rich and innovative pipeline based on this platform.
  • We are very happy to join GeneQuantum in this critical moment, when the company is growing quickly with many products entering the IND and clinical stage.

PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

Retrieved on: 
Friday, September 10, 2021
Research, Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Vor Biopharma, PureTech Health, VOR BIOPHARMA, PURETECH HEALTH

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) (Vor) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, Vors lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) (Vor) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, Vors lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).
  • Vor remains on track to report VOR33s initial clinical data in the first half of 2022.
  • The full text of the announcement from Vor is as follows:
    CAMBRIDGE, Mass., Sept. 09, 2021 Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Companys lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).
  • Therapeutic candidates receiving Fast Track designation may be eligible for priority review and accelerated approval if certain conditions are met.

DGAP-News: Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences

Retrieved on: 
Thursday, September 9, 2021

Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences

Key Points: 
  • Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
    The issuer is solely responsible for the content of this announcement.
  • Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
    Ladenburg, Germany, 9 September 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences.
  • Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma, will give a corporate presentation at the virtual global investor conference.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

VOR33 Granted U.S. FDA Fast Track Designation for AML

Retrieved on: 
Thursday, September 9, 2021

CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Companys lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).

Key Points: 
  • CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Companys lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).
  • Fast Track designation is intended to facilitate development and expedite review of products designed to treat serious and life-threatening conditions with unmet medical needs.
  • Therapeutic candidates receiving Fast Track designation may be eligible for priority review and accelerated approval if certain conditions are met.
  • Forward-looking statements in this press release include the Companys statements regarding the potential efficacy of VOR33, potential benefits VOR33 may receive in connection with its Fast Track designation and reporting initial clinical data from the VOR33 Phase 1/2a clinical trial in the first half of 2022.

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

Retrieved on: 
Monday, September 6, 2021
Clinical medicine, Medicine, Cancer treatments, Antineoplastic drugs, Immunology, Biotechnology, Antibody-drug conjugate, Immune checkpoint, Monoclonal antibody therapy, Biopharmaceutical, Chemotherapy, Immune system

(hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.

Key Points: 
  • (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.
  • In recent years, immunotherapeutic antibody drugs targeting PD-1 and PD-L1 (representing immune checkpoint inhibitors) have revolutionized cancer therapy.
  • Linker stability is extremely important in the field of antibody immune agonist conjugates.
  • GeneQuntum focuses on the development of differentiated innovation products through in-house research and development and diversified external research and development cooperation.

GeneQuantum announces Dr. Yi Xia as Senior Vice President of Statistics and Data Science

Retrieved on: 
Monday, August 30, 2021
Industry, ADC, Eisai, Statistics, Data management, Daiichi Sankyo, Rutgers University, Biostatistics, NDA, Senior, Luye, Taitung, ILDC Energy, Patient, CEO, Pleasure, Antibody-drug conjugate, Pharmaceutical industry

SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr. Yi Xia as Senior Vice President of Statistics and Data Science to further strengthen the company's management team.

Key Points: 
  • SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr. Yi Xia as Senior Vice President of Statistics and Data Science to further strengthen the company's management team.
  • "We are delighted to welcome Dr. Xia to join our management team," Dr.
  • Dr. Yi Xia received his Ph.D. in Statistics from Rutgers University.
  • Dr. Xia has rich experience in biostatistics, data management, clinical trial design, NDA submissions.

GeneQuantum announces a key leadership appointment

Retrieved on: 
Monday, August 16, 2021
GQ, Memorial Sloan Kettering Cancer Center, Health care, CEO, Bristol Myers Squibb, Drug development, Record, ILDC Energy, Antibody-drug conjugate, ADC, Pleasure, AstraZeneca, Research, Marketing, Patient, Aarhus University, Doctorate, Plasma protein binding, Cancer, Sanofi, Acceleration, Industry, Fine chemical, Pharmaceutical industry

SUZHOU, China, Aug. 15, 2021 /PRNewswire/ --GeneQuantum Healthcare, an industry leading biopharmacetucial company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced a key appointment to further strengthen GeneQuantum management team.

Key Points: 
  • SUZHOU, China, Aug. 15, 2021 /PRNewswire/ --GeneQuantum Healthcare, an industry leading biopharmacetucial company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced a key appointment to further strengthen GeneQuantum management team.
  • Gang Qin, Founder Chairman and CEO of GeneQuantum.
  • His extensive expertise and excellent leadership capability are crucial for the success of the company.
  • Dr. Wu expressed his great pleasure in joining GeneQuantum, he stated, "I am honored to join GeneQuantum.

CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Health care, Biotechnology, Health sciences, Immunology, Antineoplastic drugs, Bristol-Myers Squibb, Ipilimumab, Antibody-drug conjugate, AbbVie, Biopharmaceutical

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced the publication of three articles in peer-reviewed journals on pacmilimab (CX-072), the Company’s wholly-owned conditionally activated antibody directed against PD-L1 currently being developed in combination with praluzatamab ravtansine (CX-2009) for the treatment of triple-negative breast cancer (TNBC).

Key Points: 
  • Pacmilimab+ipilimumab was administered intravenously every 3 weeks for four cycles, followed by pacmilimab administered every 2 weeks as monotherapy.
  • We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment.
  • First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029).

ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results

Retrieved on: 
Friday, July 30, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Clinical medicine, Medicine, Antineoplastic drugs, Immunology, ImmunoGen, Antibody-drug conjugate, Health care

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2021.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2021.
  • Operating expenses for the second quarter of 2021 were $44.3 million, compared with $33.4 million for the same quarter in 2020.
  • The increase was largely driven by research and development expenses, which were $34.6 million for the second quarter of 2021, compared with $22.9 million for the second quarter of 2020.
  • General and administrative expenses for the second quarter of 2021 were $9.7 million, compared to $9.8 million for the second quarter of 2020.

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Retrieved on: 
Tuesday, July 27, 2021
Medical specialties, Clinical medicine, Immunology, Medicine, Biotechnology, Monoclonal antibodies, Antibody-drug conjugate, Immune system, Antibody

Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).

Key Points: 
  • Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
  • The antibodies generated by Glycotope are designed to deliver very high tumor selectivity.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.